Bio News
The US Food and Drug Administration (FDA) approved Revolution Medicines’ RAS inhibitor darasorasib as a treatment for metastatic pancreatic cancer. In a phase 3 clinical trial, the drug doubled overall survival. Revolution Medicines will launch the drug as an oral medication under the name Rasonk.
BIOBOOK TEAM
biobookmedia@biobook.co.krKorea National Park Service Uses AI to Identify 17 Wildlife Species, Cuts Analysis Time by 99%
Ipscell Receives Notice of Allowance for Universal iPSC Patent, Strengthening Cell Line Supply Business
Ministry of Trade, Industry and Energy and Ministry of Food and Drug Safety Sign Agreement on AI Transformation and Global Competitiveness in Biotech
Paragon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Korea National Park Service Uses AI to Identify 17 Wildlife Species, Cuts Analysis Time by 99%
Ipscell Receives Notice of Allowance for Universal iPSC Patent, Strengthening Cell Line Supply Business
Ministry of Trade, Industry and Energy and Ministry of Food and Drug Safety Sign Agreement on AI Transformation and Global Competitiveness in Biotech
